Thiotepa-Based Conditioning for Leukemia

This trial tests a new treatment approach for people with leukemia undergoing a stem cell transplant. Researchers aim to determine if a combination of drugs—Thiotepa, Busulfan, and Fludarabine—can be safe and effective when administered before the transplant. The trial includes two groups: one receiving lower-intensity treatment and the other receiving higher-intensity treatment. Suitable candidates for this trial have leukemia in remission (no signs of disease) and a compatible stem cell donor. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this new treatment approach.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial team or your doctor.

Research shows that the combination of Thiotepa, Busulfan, and Fludarabine (TBF) is generally safe for patients undergoing stem cell transplants. Studies have found that this treatment effectively prepares patients for the transplant, a crucial step in treating diseases like leukemia. However, some risks exist. Specifically, higher doses of thiotepa have been linked to an increased risk of severe graft-versus-host disease (GVHD), where the donor's immune cells attack the patient's body.

Researchers are excited about these thiotepa-based treatments for leukemia because they explore different intensity levels of conditioning regimens, which could offer more tailored treatment options. Unlike standard conditioning regimens that use just busulfan and fludarabine, these treatments incorporate thiotepa, which might enhance the effectiveness of the conditioning process. The use of thiotepa, along with varying doses of fludarabine, allows researchers to investigate the balance between treatment intensity and patient tolerance, potentially leading to safer and more effective preparation for stem cell transplants.

This trial will compare two different intensity levels of a Thiotepa, Busulfan, and Fludarabine combination to prepare leukemia patients for stem cell transplantation. Research has shown that this combination can effectively prepare the body for transplantation. In one study, some patients using this combination lived for two years without disease progression, with progression-free survival rates of 19% and 17%. Another study found a higher two-year progression-free survival rate of 71%. This treatment aims to reduce the chance of leukemia recurrence and improve outcomes by serving as a potent chemotherapy before the transplant. However, high doses of Thiotepa might increase the risk of serious side effects, such as graft-versus-host disease, where donor cells attack the patient's body. These findings demonstrate the treatment's potential but also emphasize the need for careful monitoring.¹²⁵⁶⁷